Your browser doesn't support javascript.
loading
Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
Appelberg, B G; Syvälahti, E K; Koskinen, T E; Mehtonen, O P; Muhonen, T T; Naukkarinen, H H.
Affiliation
  • Appelberg BG; Department of Psychiatry, University of Helsinki, Finland. Bjorn.Appelberg@huch.fi
J Clin Psychiatry ; 62(6): 448-52, 2001 Jun.
Article in En | MEDLINE | ID: mdl-11465522
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Buspirone / Selective Serotonin Reuptake Inhibitors / Serotonin Receptor Agonists / Depressive Disorder Type of study: Clinical_trials / Diagnostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: J Clin Psychiatry Year: 2001 Document type: Article Affiliation country:
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Buspirone / Selective Serotonin Reuptake Inhibitors / Serotonin Receptor Agonists / Depressive Disorder Type of study: Clinical_trials / Diagnostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: J Clin Psychiatry Year: 2001 Document type: Article Affiliation country: